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A B S T R A C T
An increasing human population requires a secure food supply and a cost effective, oral vaccine delivery
system for livestock would help facilitate this end. Recombinant antigen adsorbed onto silica beads and
coated with myristic acid, was released (15% (w/v)) over 24 h at pH 8.8. At pH 2, the myristic acid acted
as an enteric coating, protecting the antigen from a variety of proteases. The antigen adsorbed onto silica
particles, coated in myristic acid had a conserved secondary structure (measured by circular dichroism
(CD) spectroscopy) following its pH-triggered release. Small angle neutron scattering (SANS) was used to
measure the thickness of the adsorbed antigen, ﬁnding that its adsorbed conformation was slightly
greater than its solution radius of gyration, i.e. 120–160 Å. The addition of myristic acid led to a further
increase in particle size, with scattering data consistent with an acid thickness slightly greater than a
monolayer of fully extended alkyl chains and a degree of hydration of around 50%. Whilst adsorbed onto
the silica and coated in myristic acid, the protein was stable over 14 days at 42 C, indicating a reduced
need for cold chain storage. These data indicate that further investigation is warranted into the
development of this technology.
ã 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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The human population is predicted to reach 10 billion by 2050
(Cohen, 2003) and needs to be able to not only feed itself, requiring
the ablation of disease in livestock, but also combat infectious
disease in densely populated areas. Consequently, there exists
enormous humanitarian value in developing effective oral vaccine
delivery systems for both the clinical and veterinary arenas.
Barriers to successful oral vaccination include; (i) the proteolyticAbbreviations: SANS, small angle neutron scattering; CD, circular dichroism;
APCs, antigen presenting cells; LP, lamina propria; PP, Peyer’s patch; VDS, vaccine
delivery systems; GST–GFP, glutathione-S-transferase (GST) fused in frame with
green ﬂuorescent protein (GFP); MALDI-TOF, matrix assisted laser desorption
ionisation time of ﬂight; BCA, bicinchoninic acid assay; IPTG, isopropyl b-D-1-
thiogalactopyranoside; SDS PAGE, sodium dodecyl sulphate polyacrylamide gel
electrophoresis; MDA, maternally derived antibodies.
* Corresponding author: Tel.: +44 208 331 8207; fax: +44 208 331 9805.
E-mail address: S.C.W.Richardson@Greenwich.ac.uk (S.C. Richardson).
http://dx.doi.org/10.1016/j.ijpharm.2014.03.046
0378-5173/ã 2014 The Authors. Published by Elsevier B.V. This is an open access article unenvironment of the gastrointestinal (GI) tract (i.e. the stomach or
its equivalent in livestock, as well as commensal bacteria
inhabiting the large and small intestine) and (ii) inefﬁcient antigen
presentation which may involve either translocation into the
underlying lamina propria (LP) (containing dendritic, antigen
presenting cells (APCs)) (Clayton et al., 2006) or uptake by the
Peyer’s patch (PP), evading mucus lining the lumen. In an attempt
to circumvent these obstacles, large doses of antigen have been
administered orally (Kunisawa et al., 2012) and this approach has
met with limited success. Equivalently, live attenuated viral
vaccines have been used and despite some success, concerns have
been raised regarding safety due to either viral reversion to
virulence or viral propagation. Additionally, viral vaccines are
expensive to produce as well as being difﬁcult to store and
administer (Shaw and Davidson, 2000) and may also reduce the
yield from livestock (Müller et al., 2012).
Unstable “soft” systems fabricated from poly(lactide-co-glyco-
lide), chitosan or alginate micro- or nano-particles may extend
antigen gut residence time, reduce gastric and intestinalder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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amount of antigen required to elicit an immune response. These
systems typically have either entrapped or surface adsorbed
antigen (Wilkhu et al., 2011; Mercier et al., 2007). However,
premature release or hydrolysis of the antigen in situ has led to
antigen degradation prior to presentation to the immune system
i.e. uptake by APCs or by the PPs. Non-degradable nanoparticulate
gold or silica has been used to immobilise antigens intended for
oral vaccination (Wang et al., 2012; Tang et al., 2011). Nano-
particulate silica has been proposed as a component of medicines
designed to treat diseases affecting bone, tendons, diabetes,
inﬂammation and cancer (Vallet-Regi and Ruiz-Hernandez,
2011). Since, in this instance, nano-particulate silica would be
delivered orally, it was hypothesised that the vaccine delivery
systems (VDS) proposed herein would not be subject to trans-
cytosis across the epithelial lining of the gut. This is due to its
diameter being too big for the clathrin or caveolae-mediated
cellular uptake (dos Santos et al., 2011) necessary for transcytosis
(Tuma and Hubbard, 2003) (i.e. greater than 2–300 nm). Silica has
also been shown to exhibit low toxicity at concentrations of up to
500 mg/ml in macrophages (Herd et al., 2013) and is amenable to
surface functionalisation, making it an attractive delivery system
component (Wen et al., 2013).
In an effort to stabilise adsorbed proteins through the
proteolytic environment of the GI, the encapsulation of silica
adsorbed antigen has been attempted using polymers such as poly
(acrylic acid). The polymer coat designed to be unstable at higher
pH (i.e. within the lumen of the small intestine) whilst being stable
at low pH (i.e. within the stomach) (Song et al., 2007) provided a
smart, enteric, antigen controlled release system. The aforemen-
tioned systems often have demonstrated low bioavailability
proﬁles (Sakuma et al., 1997) and consequently, myristic acid,
previously used as a food additive, extracted from nutmeg
(Burdock and Carabin, 2007) was evaluated as an enteric coat.
The systemwas characterised by determining the size of the silica
as well as the antigen (a recombinant protein) corona. The size of the
myristic acid coated antigen adsorbed silica was also determined.
The effectiveness of the myristic acid coat to protect the underlying
protein antigen from protease K and an in vitro stomach model was
also assessed. Protein release was documented as a function of pH
and the secondary conformation of the protein antigen (glutathi-
one-S-transferase fused in frame with green ﬂuorescent protein
(GST–GFP)), was monitored in the native form as well as post-
release (with and without myristic acid coating). The conservation
of protein conformation may, in this instance, be used to drive both
transcytosis and antigen uptake, mediating immunisation. Finally,
antigen stability was also assessed over a deﬁned time period
(14 days) above ambient temperature (42 C) in order to assess the
impact of formulation upon vaccine cold-chain storage.
2. Materials and methods
2.1. Materials
2.1.1. Equipment
The orbital shaker and microtitre plate reader were from Thermo
Fischer, (Loughbourgh, UK). The mini-PROTEAN1 tetra cell, mini
trans-blot, electrophoretic transfer cell and PowerPac HCTM power
supply were supplied by BioRad (Hemel Hempstead, UK). The
French Press and Sorvall1 RC6 Plus, centrifuges were from
ThermoFisher Scientiﬁc (Loughborough, UK). The matrix assisted
laser desorption ionisation time of ﬂight (MALDI-TOF) mass
spectroscopy was performed on an Autoﬂex MALDI-TOF system
(Bruker, Coventry, UK). The freeze dryer (Wizard 2.0 VirTis) was
supplied by SP Scientiﬁc (Suffolk, UK). The ChirascanTM was
supplied by Applied PhotoPhysics, (Surrey, UK). The zeta seizer(Nano Z) was supplied byMalvern (Worcestershire, UK). Small angle
neutron scattering was performed in 2 mm path length cylindrical
(“banjo”) fused silica cuvettes (Hellma GmbH & Co., Müllheim,
Germany). Fluorescence spectrawere measured using a Fluoromax-
4 spectroﬂuorometer (Horiba Scientiﬁc, Middlesex, UK).
2.1.2. Reagents
General Laboratory reagents were purchased from Sigma (Dorset,
UK). Specialised reagents: bicinchoninic acid assay (BCA) assay kit,
glucose, ampicillin, reduced glutathione, isopropanol, tris-base, PBS
tablets, lithium chloride, ethylenediaminetetraacetic acid di-sodium
salt (EDTA), glycerol, agarose, sodium hydroxide, potassium acetate,
ammonium acetate, pancretin, porcine bile, myristic acid, guanidi-
nium HCl, acetone, pepsin, isopropyl b-D-1-thiogalactopyranoside
(IPTG), protease K, sodium azide, nitrocellulose membrane (0.2 mm
pore size) and bovine serum albumin (BSA) were purchased from
Sigma (Dorset, UK). Coomassie brilliant blue G-250, acrylamide, bis-
acrylamide, ammonium persulphate, 2-mercaptoethanol, sodium
dodecyl sulphate (SDS) were purchased from BioRad (Hemel
Hempstead, UK). Tris-base, Bacto-tryptone, Bacto-yeast extract,
ampicillin, glycerol, imidazole, sodium chloride, and glycine were
purchased from Fischer (Leicestershire, UK). Ni2+SepharoseTM(high-
performance) was supplied by GE Healthcare (Buckinghamshire,
UK). Silicon(IV) oxide powder, (0.5 micron), was supplied by Alfa
Aesar (Lancashire, UK).
2.2. Recombinant protein production
The plasmid (pGST–GFP (GenBank JN232535.1)) has been
described in detail previously (Urbanowski and Piper, 1999) and
was a kind gift from Professor Robert Piper (University of Iowa, USA).
For protein expression, pGST–GFP was transformed into E. coli
MC1061 (Invitrogen, Paisley, UK) and grown overnight (to satura-
tion) in 2xYT media containing 25 mg/ml ampicillin with or without
deuterium oxide in place of water. The latter was used to produce
partially deuterated protein. The saturated 10 ml overnight culture
was used to inoculate 1000 ml of 2xYT media containing 25 mg/ml
ampicillin, which was grown at 37 C shaking at 180 rpm for 4 h.
Gene expression was induced by adding IPTG (1 mM), and
continuing to incubate the culture for a further 4 h at 37 C shaking
at 180 rpm. The bacteria were lysed using a French Press pressure
cell (ThermoFisher Scientiﬁc, Loughborough, UK) set to 1500 psi,
cleared by sedimentation at 20,000  g (4 C) and subject to afﬁnity
enrichment using glutathione-conjugated Sepharose 4b (GE
Healthcare, Bucks, UK), in accordance with the manufacturer’s
instructions. Sodium azide (0.2% (w/v)) and a 5 concentration of
protease inhibitors (CompleteTM EDTA free protease inhibitor
cocktail (Roche, Burgess Hill, UK)), were added after the lysis of
the E. coli MC1061. Enriched protein was then dialysed against PBS.
2.3. Recombinant protein characterisation
After GST–GFP enrichment (Section 2.2), protein concentration
was determined using the BCA assay against BSA standards. Care
was taken to ensure the readings were within the linear range of
the assay. Having assessed protein concentration, GST–GFP
ﬂuorescent spectra was recorded by ﬁrst determining the protein’s
absorption proﬁle. Having determined the wavelength at which
maximum absorption (lambda maximum) occurred (490 nm), this
wavelength was then used to excite the protein sample to
determine the emission proﬁle.
2.3.1. SDS PAGE and Coomassie R-2501 brilliant blue staining
Afﬁnity enriched GST–GFP (Section 2.2) was further charac-
terised by sodium dodecyl sulphate polyacrylamide gel electro-
phoresis (SDS PAGE) and Coomassie G2501 brilliant blue staining
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the apparent molecular weight of the protein (Fig. 1
(panel a). This was performed in accordance with the mini-
protein Tetra Cell manufacturers instructions (BioRad, Hemel
Hempstead, UK).
2.3.2. Western blotting and imumunodetection
Immobilised protein was obtained by separating protein
samples using SDS PAGE (Section 2.3.1) and electroblotting using
the mini trans-blot, electrophoretic transfer cell (BioRad, Hemel
Hempstead, UK) and following the manufacturer’s instructions.
Protein detection was performed using both GFP- (A11122,
Invitrogen, Paisley, UK) and GST-speciﬁc (ab19256, Abcam, Cam-
bridge, UK) monoclonal, primary antibodies (Fig. 1 (panel a)).
Antibody detection was performed using a horseradish peroxi-
dase-conjugated secondary antibody (mouse IgG speciﬁc) and
picostable enhanced chemiluminescence reagent (GE Healthcare,
Bucks, UK) in accordance with the manufacturer’s instructions.
2.3.3. MALDI-TOF mass spectroscopy
MALDI-TOF MS was performed using an Autoﬂex MALDI-TOF
system (Bruker, Coventry, UK). Protein identiﬁcation by peptide
mass ﬁngerprinting was also carried out to obtain GST–GFP
sequence information. To this end, GST–GFP was digested with
trypsin following standard procedures (Cottrell, 1994). The
resulting digest mixture was analysed by MALDI-TOF MS and
the experimental mass values were compared with reference
peptide mass values, calculated by applying the enzyme cleavage
rules (Pappin et al., 1993).Fig. 1. Fig. 1 documents the characterisation of the recombinant antigen used herein (
Western immunoblotting using primary antibodies speciﬁc for both GST and GFP (panel a
from GST–GFP, mapped back to the predicted sequence (derived from the plasmid GenB
GST–GFP ORF within pGST–GFP (JN232535.1) is shown. The amino acids in red were ide
black was not identiﬁed as being covered by tryptic fragments. (For interpretation of the 
this article.)2.4. Protein immobilisation
Puriﬁed, recombinant protein (GST–GFP) (10 mg) was incubat-
ed with silica beads (Alfa Aeser, Lancashire, UK) (1 mg) in sodium
acetate buffer (pH 5.6) on a rotating rack at 4 C overnight. The
protein-adsorbed silica was subject to sedimentation at 6000  g
for 2 min. Supernatant was removed and two washes with sodium
acetate buffer were performed to remove any non-bound protein.
Non-bound protein was analysed using the BCA assay and
adsorption plots derived.
2.5. Myristic acid coating
Serial dilutions of myristic acid were performed to explore the
effects of surface coverage, spanning sub-monolayer through to
the multi-layer deposition of myristic acid. Protein adsorbed silica
beads (Section 2.4) were immersed in 5 ml pentane containing the
indicated amounts myristic acid. Pentane was allowed to evaporate
during sonication at 23.5 W/cm2 for 30 min or until the pentane
had evaporated. Myristic acid coated particles were then freeze-
dried using a VirTis Wizard 2.0 freeze dryer (thermal cycles as
described (see Supplementary data)). Unless otherwise noted (i.e.
during the SANS experiments) 1 mM myristic acid/g silica was used
to coat the antigen adsorbed silica (Section 2.4).
2.6. Particulate characterisation
2.6.1. Assessment of particle composition using zeta sizing
Measurements were taken using a 1 ml volume and ten repeats
were performed to maximise the signal to noise ratio. TheGST–GFP). Enriched GST–GFP was analysed by SDS PAGE and Coomassie staining,
) and MALDI-TOF MS (panel b) as well as via the analysis (by MS) of tryptic fragments
ank JN232535.1) (panel c). The entire predicted protein sequence derived from the
ntiﬁed as tryptic fragments within GST and the area in blue, within GFP. The area in
references to colour in this ﬁgure legend, the reader is referred to the web version of
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minutes before the samples were loaded.
2.6.2. Assessment of particle composition using small angle neutron
scattering (SANS)
SANS experiments to assess the diameter of the silica and silica-
adsorbed protein (Section 2.4) were performed on instrument D11
(lowest momentum transfer and lowest background instrument)
at the Institut Laue – Langevin, Grenoble, France. The scattering
was measured in 2 mm Hellma cells placed within a rotating rack,
to obviate the slow settling that occurs within these systems. Three
sample detector distances (1.2, 8 and 39 m), with appropriate
collimation, were employed, using incident neutrons with
wavelength 8 Å. Data were normalised by reference to a ﬂat
scatterer (1 mm H2O at ILL, ﬂood source at ISIS) and then adjusted
to absolute scattering cross sections by reference to a standard
sample.
The data describing the myristic acid coated, antigen adsorbed
silica (Section 2.5) was collected using the SANS 2D beamline at the
ISIS pulsed neutron source, Didcot, UK, also using 2 mm Hellma
cells placed in a rotating rack. The SANS data from both
instruments were ultimately ﬁtted to an analytical multi-shell
model, assuming a spherical geometry using the program FISH
(Heenan, 1989).
2.7. Protein stability assay
2.7.1. Protein stability assay using protease K
Initially the sensitivity of GST–GFP to protease K was established.
As the ﬂuorescence of the GFP portion of the GST–GFP protein was
found to persist after protease digestion (500 mg GST–GFP with
100 mU of protease K in PBS incubated for 60 min at 37 C shaking at
180 rpm) (Section 2.2), a GST “pull down” (sedimentation) assay was
used to assess protein integrity followed by Western immunoblot-
ting (to monitor molecular weight). This assay was performed using
glutathione-conjugated Sepharose 4b to sediment (21,000  g for
60 s at room temperature) intact protein from the digestion reaction
(the supernatant was discarded) prior to Western immunoblotting
performed as previously described. This experiment allowed an
assessment of the unit value of protease appropriate for the
digestion of a known amount of GST–GFP immobilised upon the
silica, as well as providing a positive control for protease K mediated
digestion. To assay immobilised and myristic acid coated antigen
stability, 100 mU of protease K was incubated with 500 mg
equivalent of protein-adsorbed silica in PBS at 37 C for 60 min
(Fig. 3). Where indicated the samples were kept in a humidiﬁed
atmosphere at 42 C for 14 days prior to digestion and analysis by
Western immunoblotting using a GFP-speciﬁc primary antibody
(Section 2.3.2).
2.7.2. Protein stability assay using an in vitro stomach model
Myristic acid coated, protein adsorbed silica (Section 2.5) was
placed in HCl (0.1 M) with pepsin (40 mg/ml) (Sigma, Dorset, UK)
(Glahn et al., 1998). After an hour, NaHCO3 (0.1 M) was used to
neutralize the pH (pH 7.4) and porcine bile (12 mg/ml) (Sigma,
Dorset, UK) and pancreatin (2 mg/ml) (Sigma, Dorset, UK) was
added, simulating lumen of the duodenum. After incubation in the
in vitro simulated stomach model (4 h, 37 C), results were analysed
by Western immunoblotting and densitometry (Section 2.2 and
2.3.2).
2.8. Protein release assay
Freeze dried, myristic acid coated, protein absorbed silica
(Section 2.5), was incubated in PBS over the indicated pH ranges, at
37 C for 2 h (Fig. 4 (panel a)). After this time the sample wassedimented at 6000  g for 2 min at room temperature. The
supernatant was then collected and analysed for release studies,
via Western immunoblotting and BCA assay. Protein that remained
adsorbed to silica beads was analysed via Western immunoblot-
ting, and mass balance performed, again by Western immunoblot-
ting. Protein was quantiﬁed by densitometry using ImageJ (NIH,
Maryland, USA).
2.9. Analysis of protein structure by circular dichroism spectroscopy
Released protein was inserted into a 0.1 mm quartz cuvette
(approximate concentration of 0.2 mg/ml) and analysed at wave-
lengths between 190–260 nm, bandwidth 1 nm, 20 C in PBS. Blank
(PBS) was subtracted from the data and plots obtained using Prism
software (GraphPad, California, USA).
3. Results
3.1. Protein characterisation
Having isolated highly enriched (i.e. one protein band visible in
an SDS PAGE Coomassie stained gel), recombinant, GST–GFP from
E. coli MC1061 lysate, the protein antigen, was characterised by
Western blotting and immunodetection (Fig. 1 (panel a)) and also
mass spectroscopy (Fig. 1 (panel b and c)). The protein was
immunoreactive to both GST- and GFP-speciﬁc antibodies and in a
departure from the mass predicted from an in silico analysis of the
plasmids sequence, the mass and amino acid sequence of the
protein was determined following a tryptic digest (Fig. 1 (panel c)).
The deconvolved MALDI-TOF data described the enriched GST–GFP
protein to have a mass of 53.6 kDa (Fig. 1 (panel c)), corroborating
the data from the gel electrophoresis experiments including
Western analysis. The variance from the in silico data (from
GenBank JN232535) is very likely due to GST–GFP missing the N-
terminal methionine and the 69 C-terminal amino acids, which
would give a mass of 53,600.00 Da versus the observed mass of
53600.22 Da. Given that the missing portion of the protein was
derived from Plasmodium spp., rather than from GFP, the omission
was deemed of no consequence to this study. The ﬂuorescence
emission spectrum of GST–GFP was identical to the published
spectra of GFP (Pollok and Heim, 1999) (data not shown).
3.2. Particle characterisation
Approximately 75% of GST–GFP (500 mg) was adsorbed onto the
silica beads (50 mg) by decreasing the pH to 5.6 in sodium acetate
buffer as analysed by BCA assay (Section 2.5). Thus, a 1:10 ratio of
protein:silica was required for optimal protein loading. Unique to
this work, pentane was used as a solvent for the myristic acid and
also used to coat the protein-adsorbed silica. The silica, antigen
adsorbed silica and the antigen adsorbed, myristic acid coated
silica were characterised using SANS and by assessing zeta
potential. SANS deﬁned the silica to be approximately
6600  290 Å in diameter, at the upper most end of the scale
quantiﬁable by SANS, but comparable with the light scattering
estimate (silica diameter 6230 Å). However, SANS was used to
characterise the thickness of the protein corona surrounding the
silica using a series of contrast-matched samples (Fig. 2), requiring
both deuterated and hydrogenated GST–GFP. Contrast variation
allowed the relative scattering from the core particle and protein
coat to be independently varied. The multiple datasets were then
simultaneously ﬁtted to a single parameterised model to greatly
increase the delineation of the quantities returned in the ﬁtting.
Taken together, the SANS data has shown that the protein coated
silica particles appeared discrete, (i.e. not aggregating), with a
corona of adsorbed protein measuring 120–160 Å (12–16 nm). The
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and the known composition of the system, suggesting a water
content within the protein layer of some 30–40% (w/v). The
thickness of the protein layer is approximately double the
theoretical GST–GFP radius of gyration (8.4 nm) (calculated
using I-TASSER (Roy et al., 2010)) consistent with polymer
adsorption theories (Fleer et al., 1993). These values are also
in good agreement with the zeta sizing data, describing the
protein-adsorbed silica’s diameter to be approximately 6310 Å,
showing an increase in particle size of 10  3.2 nm upon protein
adsorption.
The above system was similarly characterised by SANS after
protein adsorption and myristic acid coating with 473 mM of
myristic acid/g silica (affording almost 100% protease protection
(Fig. 3)). As before, the samples had to be continually rotated whilst
suspended in solution on the beamline. The data presented in Fig. 2
(panels c and d), were analysed taking the particle/protein layer
analysis as a starting point (King et al., 2000). Two contrasts
against deuterium oxide were examined, one in which the protein
was hydrogenous and there were no distinct steps in the scattering
length density proﬁle (rparticle = 3.6  104 nm2, rprotein = (partial-
ly deuterated) 4.0  104 nm2, (hydrogenated) 2.0  104 nm2,
racid = 3.2  104 nm2), the second where the protein was
deuterated introducing a step at both the silica/protein and
protein/myristic acid interfaces. Taken together, best ﬁts wereFig. 2. Fig. 2 shows the characterisation of the VDS described herein by SANS. Panel (a) d
adsorbed onto the silica particles. Panel (b) records the SANS data and “mathematical ﬁ
previously outlined (in panel a). Panel (c) describes the SANS experiment designed to mea
GFP. Panel (d) describes the SANS data and the associated modelling of the “mathematic
437 mM of myristic acid/g silica. These data describe a particle with mean diameter 6600
disordered phase approximately 20 Å deep extending beyond the protein corona.observed when the thickness of the hydrated protein layer was
held at 120 Å ((’) H2O 50%) with the thickness of the enteric layer
around 20 Å, comparable to the fully extended length of the
molecule. The absolute scattering intensities, whilst imprecise due
to the sample instability, suggest that the enteric coating is also
hydrated to a level of around 50%.
3.3. Enteric protection, protein release and analysis
To characterise the degree of protection provided by the
myristic acid coat, a series of samples were prepared that spanned
an input of 10 pM–1 mM myristic acid/g silica (Fig. 3). Optimal
protection was observed (i.e. 100% (w/v) protein recovery after
incubation with 500 mU of protease K at 37 C for 1 h) after coating
with 1 mM myristic acid/g of protein-adsorbed silica (Fig. 3 (panel
a)). Further protection is evident from an in vitro digestion model
simulating the stomach, after the VDS was sonicated during
myristic acid coating (but not after stirring during myristic acid
coating) (Fig. 3 (panel a)). At quantities below 1 mM myristic acid,
protein degradation was evident (Fig. 3 (panel b)). At a myristic
acid concentration above 1 mM, the myristic acid coated, protein
adsorbed silica was stable over 2 weeks at 42 C (Fig. 3 (panel b)).
After myristic acid coating, protein remained adsorbed to the
silica surface at pH 3.6 and pH 5 and was released at pH 8.8 (7%
(w/v) after 2 h at 37 C (Fig. 4 (panel a)). Released protein waseﬁnes a series of contrast matching experiments used to deﬁne the protein corona
ts” i.e. a core–shell model, (Guinier and Fournet, 1955) describing the experiment
sure the extent of protein coating, utilising both deuterated and hydrogenated GST–
al ﬁt” that best describes the diameter of the VDS after myristic acid coating using
  290 Å and a protein corona of 120–160 Å. The myrisitic acid may be measured as a
Fig. 4. Fig. 4 documents the release of GST–GFP from VDS in response to pH. Panel (a) records release over 24 h. Protein detection was performed by immunoblotting using an
anti-GFP polyclonal primary antibody. As was recorded, protein was released from the VDS into the supernatant at pH 8.8 after 2 h. Panel (b) shows protein release from the
VDS at pH 8.8 over 24 h. These data show approximately 15% protein release from the myristic acid coated protein (1 mM myristic acid/g silica) adsorbed silica. Fig. 4 (panel c)
shows the CD spectra from: protein released from protein-adsorbed myristic acid coated silica (——), the native, unformulated protein (GST–GFP) ( . . . .) and protein released
from protein-adsorbed silica ( ). GST–GFP release from the myristic acid coated silica displayed an almost identical secondary conformation pre- and post-release, with or
without myristic acid coating. These data were used to derive molar elipticity for each sample, which was recorded in Table S1.
Fig. 3. Fig. 3 documents the protection afforded to the protein antigen after varying degrees of myristic acid coating ([Myristic acid]/g silica). Panel (a) documents the
protection afforded by the myristic acid coated (1 mM/g silica) to GST–GFP from both protease K (500 mU, digestion over 1 h at 37 C) and during an in vitro stomach simulation
(4 h digestion at 37 C). Panel (b) shows the protection of GST–GFP in relation to a varying amount of myristic acid after 14 days storage at 42 C. Here 100 mU of protease K was
used and the VDS were exposed to the protease K for 1 h at 37 C. Protein quantitation was performed by Western immunoblotting relative to a set of standards being careful to
stay within the linear range of the assay. Representative blots are shown using a GFP speciﬁc primary antibody and correspond to the points indicated on the graph (i.e.
amount of myristic acid used).
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Table 1
CD spectra (molar elipticity) of antigen: pre-adsorption and post-release.
Molar elipticity GST-GFP (%) Released protein
No myristic acid (%) Myristic acid coat (%)
a-Helix 16.9 16.9 16.9
b-sheet 20.8 20.8 20.8
Random coil 43.3 43.3 43.3
270 M.W. Pettit et al. / International Journal of Pharmaceutics 468 (2014) 264–271detected using Western blotting and immunodetection and
progressively increased over 90 min before reaching a plateau of
up to 15% (w/v) after 24 h (Fig. 4 (panel b)). The CD spectra of
released GST–GFP (Fig. 4 (panel c) and Table 1) demonstrated the
conservation of protein secondary structure following its release
from the myristic coated VDS.
4. Discussion
Fig. 5 depicts a cartoon describing the way this potential VDS
may behave based upon the data presented herein. These data have
demonstrated the feasibility of using myristic acid coated, antigen
adsorbed silica as part of a VDS strategy by characterising both the
system in its entirety as well as the protection and release of the
protein (antigen) from this system. The technology described
herein may provide a way to stabilise protein conformation
through the proximal gastrointestinal tract (Fig. 3) and, if applied
to a recombinant protein carrier (capable of mediating transcytosis
from the lumen of the small intestine (into the LP)), one could
envisage a strategy for the oral delivery of vaccine epitopes.
Conservation of protein structure is particularly important (Fig. 4),
as previous reports have documented antigen conformation being
critical for immunisation (Arnold et al., 2003). The conservation of
secondary structure post-release (from the VDS), allows the
inclusion of recombinant domains that could mediate transloca-
tion, from the lumen of the GI into the LP (containing APCs) (Wang
et al., 2012). Cholera toxin B chain is reported to provide such
“transporter” functionality (Torgersen et al., 2001).
The data describing protein protection in relation to the myristic
acid stoichiometry around the so-called Pockels point, is consistent
with data from: (i) the SANS experiments (Figs. 2 and 3) and (ii)
protection from both protease K and the in vitro stomach simulation
(Fig. 4). This is assuming a minimum area per fatty acid head group
of approximately 20 Å2 (Pockels, 1891) and a spherical surface area
of 3.95 m2/g (after accounting for an additional 12–16 nm proteinFig. 5. Fig. 5 is a cartoon showing the proposed mode of action of the VDS. A change in pH
trigger myristic acid and protein dissolution. It was hypothesised that the myristic acidcorona). Given that Pockels point here would be at approximately
33 mM myristic acid/g silica and that the SANS data was performed
at a myristic acid input of 437 mM/g silica, the SANS data is
consistent with myristic acid coverage slightly in excess of Pockels
point. This would point to a fairly inefﬁcient coating methodology.
However, as protease protection was evident (Fig. 3), it was deemed
adequate. The above data, in conjunction with the predicted degree
of hydration of both the protein and fatty acid layer, imply that the
lipid coating is not highly ordered. Given the methodology used to
coat the particles, this is notentirely unexpected.Furthermore as: (i)
protease protection (Fig. 3), (ii) pH-triggered protein release (Fig. 4)
and (iii) the release of protein with a highly conserved secondary
structure (Fig. 4 and Table 1) was observed, the methodology was
again deemed adequate. The speciﬁcs governing the interactions
between the myristic acid and the protein have not been considered
beyond myristic acid deposition in response to the removal of its
solvent. This is likely to be very complex interaction, dependant
upon protein speciﬁc chemistry. Its is an on going subject of
investigation and one that will be evaluated once a speciﬁc antigen
and “transporter” domain have been identiﬁed.
It should be noted that the in vitro stomach model adopted here
does not comply with the standards set by the FDA or in the
Pharmacopeia. However, within the context of establishing proof
of concept were thought to be adequate.
The experiments described herein (Fig. 3) also described
encapsulated, adsorbed protein stability over the experimental
time frame (i.e. 2 weeks at 42 C). Although this experiment was
not conducted to ICH standards, it provided some preliminary
evidence supporting the hypothesis that a consequence of the
formulation described may be a reduced need for cold-chain
storage (i.e. stabilisation), reducing cost.
Myristic acid coating, protease protection and dissolution over
the pH range documented were hypothesised to be driven by the
pKa of the myristic acid. Given that the pKa of myristic acid is 4.9, at
pH 2.0 (i.e. the pH of the stomach), the myristic acid would be
protonated, carrying a net neutral charge. As the pH was
neutralised (distal to the stomach), the myristic acid would
deprotonate, leaving it with a net negative change driving
equilibrium towards dissolution.
The size of the solid phase core material, the release rate of the
protein from the solid phase core and the adjuvant effect of the
core upon a nominated antigen, will require optimisation in the
future. Protein release rate may be further modulated (or
optimised) in the future via silica surface functionalisation from the acidic (stomach) to a more alkaline (intestine) environment is proposed to
 coat could offer protection against proteases.
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the primary structure of the recombinant protein. However, at this
point, it is not known whether the further optimisation of protein
release is necessary, as colloids associated with protein antigens
may act as adjuvants (Wang et al., 2012). If the VDS size were to be
reduced (to less than 100 nm), it may be possible to envisage the
entire VDS being transported to the LP (containing APCs), diffusing
through the mucus layer (Aljayyoussi et al., 2012), and therefore,
eliminating the need for antigen release. Equivalently it may also
be possible to use “invasin” family proteins derived from microbes,
such as Yersinia spp., to augment the uptake of the particle or the
released protein into microfold cells of the PP (Tuma and Hubbard,
2003) facilitating antigen presentation to the immune system.
Until the efﬁciencies of the systems described are quantiﬁed
empirically, it is hard to envisage which will ultimately be the more
successful at oral vaccine delivery.
This system may also be amenable to multiple rounds of self
administration by large numbers of livestock via mixing it with
food, removing the problems associated with the laps in protection
from maternally derived antibodies (MDA) seen in species such as
Gallus spp. as young birds mature (Clench, 1999). As there is little
synchronicity associated with the relaxation of MDA associated
protection in a ﬂock, multiple rounds of VDS administration might
be a cost effective way of overcoming the MDA mediated
neutralisation of vaccination. This could be achieved not via the
addition of the VDS to drinking water, but by adding the VDS to
chicken feed negating the need for specialised supervision over
multiple rounds of VDS administration to multiple individuals.
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